胸主动脉瘤外科干预效果的系统综述与荟萃分析
结果显示TEVAR在破裂和完整动脉瘤中均降低30天死亡率,并减少截瘫/脊髓缺血和肺部并发症,缩短住院和ICU时间;卒中风险降低无统计学意义。
要点
- TEVAR降低破裂和完整胸降主动脉瘤的30天死亡率。
- TEVAR减少截瘫/脊髓缺血和肺部并发症,卒中风险降低无统计学意义。
- TEVAR缩短住院和ICU时间,杂交方法也缩短住院时间。
核心结论
- 观察性证据显示,与开放修复相比,TEVAR降低胸主动脉瘤30天内死亡、截瘫、脊髓缺血和肺部并发症风险,并缩短住院和ICU时间。
主要发现
- TEVAR与破裂动脉瘤30天死亡率降低相关(OR 0.58;95%CI 0.38-0.88)。
- TEVAR与完整动脉瘤30天死亡率降低相关(OR 0.6;95%CI 0.36-0.99)。
- TEVAR降低截瘫或脊髓缺血风险(OR 0.35;95%CI 0.2-0.61)。
- TEVAR降低肺部并发症风险(OR 0.41;95%CI 0.37-0.46)。
- 卒中风险降低无统计学意义(OR 0.89;95%CI 0.76-1.03)。
关键数值与推荐
- TEVAR相比开放修复,住院时间平均减少5.17天(95%CI -7.77至-2.57)。
- TEVAR相比开放修复,ICU时间平均减少5.89天(95%CI -9.65至-2.12)。
- 杂交方法相比开放修复,住院时间平均减少8.83天(95%CI -14.37至-3.29)。
- 杂交方法相比开放修复,ICU时间平均减少3.17天(95%CI -5.54至-0.97)。
临床怎么用
- 对于胸降主动脉瘤患者,TEVAR可考虑作为开放修复的替代方案以降低30天死亡和脊髓缺血风险。
局限性
- 纳入研究为观察性证据,存在高混杂风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: A systematic review and meta-analysis was conducted to evaluate the effectiveness of thoracic endovascular aortic repair (TEVAR) and open repair in patients with descending thoracic aortic aneurysms (TAAs). METHODS: PubMed, Ovid MEDLINE, Ovid Embase, EBSCO Cumulative Index to Nursing and Allied Health Literature, and Scopus were searched from each database's inception to January 29, 2016. We selected studies that compared the two approaches in adults with TAAs and reported 30-day mortality or procedure complications. Two reviewers independently extracted data, and conflicts were resolved by consensus. Random-effects meta-analysis was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). The main outcomes and measures were all-cause 30-day mortality, 30-day paraplegia or spinal cord ischemia, stroke, pulmonary complications, and length of hospital and intensive care unit (ICU) stay. RESULTS: Twenty-seven studies of moderate methodologic quality were included. TEVAR was associated with lower 30-day mortality in ruptured (OR, 0.58; 95% CI, 0.38-0.88) and intact (OR, 0.6; 95% CI, 0.36-0.99) aneurysms. Paraplegia or spinal cord ischemia (OR, 0.35; 95% CI, 0.2-0.61) and pulmonary complications (OR, 0.41; 95% CI, 0.37-0.46) were reduced in patients undergoing TEVAR, whereas a reduction in stroke risk was not statistically significant (OR, 0.89; 95% CI, 0.76-1.03). Pooled mean difference in length of hospital and ICU stay was lower for TEVAR by -5.17 days (95% CI, -7.77 to -2.57) and -5.89 days (95% CI, -9.65 to -2.12), respectively. Three studies showed that compared with open repair, a hybrid approach reduced hospital stay (pooled mean difference, -8.83 days; 95% CI, -14.37 to -3.29) and ICU stay (pooled mean difference, -3.17 days (95% CI, -5.54 to -0.97), with minimal evidence on other outcomes studied. CONCLUSIONS: Observational evidence at high risk of confounding suggests that compared with open repair for TAA, TEVAR reduced risk of mortality, paraplegia, spinal cord ischemia, and pulmonary complications within 30 days of intervention. Patients undergoing TEVAR also had shorter length of hospital and ICU stay compared with patients undergoing open repair.
引用
- Alsawas M, Zaiem F, Larrea-Mantilla L, et al. Effectiveness of surgical interventions for thoracic aortic aneurysms: A systematic review and meta-analysis. J Vasc Surg. 2017. PMID: 28756047. doi:10.1016/j.jvs.2017.05.082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。